Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00113932 · ClinicalTrials.gov registry record · Phase 2
UARK 2003-41: A Study of High-Dose Density Therapy in Patients With Multiple Myeloma
A Phase 2 study, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
NCT00113932 is a Phase 2 study that has completed, run by University of Arkansas. The registered enrollment target is 140 participants.
The verdict
NCT00113932, a Phase 2 study, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if treating multiple myeloma (MM) patients with more intense chemotherapy and autologous transplant (high dose density therapy) early in the disease course will result in better treatment outcomes compared to patients treated in the past.
Interventions
- PROCEDURE High-Dose Density Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2003-12 |
| Est. Completion | 2010-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00113932
The ClinicalTrials.gov registry entry for NCT00113932 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which High-Dose Density Therapy is the first listed.
NCT00113932 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00113932 about?
NCT00113932 is a clinical study titled "UARK 2003-41: A Study of High-Dose Density Therapy in Patients With Multiple Myeloma". The purpose of this study is to find out if treating multiple myeloma (MM) patients with more intense chemotherapy and autologous transplant (high dose density therapy) early in the disease course will result in better treatment outcomes compared to patients treated in the past.
What is the current status of trial NCT00113932?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2003-12. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00113932?
The interventions under investigation include: High-Dose Density Therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00113932?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.